Maddi Hebebrand, MC, Associate Editor

Studies show conflicting serum levels of zinc and copper in vitiligo patients, indicating a need for further research.

Developed by a panel of global dermatology experts, the SQS addresses the multifaceted nature of skin quality.

The app demonstrated high sensitivity (92.0%) and specificity (95.5%) in identifying skin changes through a controlled testing environment.

In a Dermatology Times Case-Based Roundtable event, Chesahna Kindred, MD, MBA, FAAD, reviewed 2 cases of patients with vitiligo treated with ruxolitinib cream.

The new delivery systems for bimekizumab-bkzx represent an upgrade over previous 1 mL options, reducing the frequency of injections required.

The study design emphasizes elevated endpoints, particularly joint health, ensuring that the most relevant outcomes are prioritized for patient care.

Efinaconazole demonstrated enhanced efficacy in treating nail fungal infections, thanks to its high penetration capability and low keratin binding.

Researchers behind the trial saw a decrease in the Severity of Alopecia Tool (SALT) score from 31 to 11.2 after 3 months of treatment with brevilin-A.

Researchers behind the study emphasized the urgent need to enhance the diagnostic skills of primary care practitioners to improve early detection of psoriasis.

Significant reductions in itch scores and improved assessments of PN severity and quality of life were observed throughout the study.

A recent review found clinical trials for HS lack diversity, limiting understanding of treatment efficacy for SOC populations.

Mease, the lead investigator on the trial, spoke about comparing varying mechanisms of action, primary and secondary endpoints, and how the results of BE BOLD could affect treatment choices.

Experts shared pearls for acne and rosacea care at Maui Derm NP+PA Fall.

A recent review found hair loss can severely impact self-esteem and body image, leading to social anxiety and emotional distress among affected youth.

In a Dermatology Times Case-Based Roundtable event, Andrew Alexis, MD, MPH, FAAD, reviewed 3 cases of patients with vitiligo treated with ruxolitinib cream.

Melinda Gooderham, MSc, MD, FRCPC, emphasized the significance of the study’s results, showcasing stable laboratory parameters over a 12-week trial.

A poster presented at the EADV Congress revealed the drug's long-term efficacy in treating AD, particularly in the head and neck regions.

The expanded dosage aims to provide healthcare providers with greater flexibility in treating larger or multiple areas affected by AK.

While researchers found both therapies effective in long-term use, they stated secukinumab showed quicker improvements in QoL.

Hypothyroidism and Hashimoto's thyroiditis were found to significantly increase the risk of developing AA, unlike hyperthyroidism.

A recent study indicated that 43.3% of lesions achieved a high efficacy score following Alexandrite laser therapy.

Researchers behind the review suggested that future research should prioritize large-scale trials to confirm abrocitinib's long-term safety and efficacy in various skin disorders.

This marks the first head-to-head trial of an IL-17A/F inhibitor against an IL-23 inhibitor in psoriatic arthritis treatment.

The company plans to release full 52-week OLE data for ESK-001 in early 2025, building on positive interim results.

After releasing promising data from several clinical trials, Burnett discussed the importance of studying efficacy and safety across diverse populations.

Nearly 44.2% of patients achieved HiSCR100, indicating a complete resolution of HS symptoms by the end of the 2-year period.

Key highlights of the presentations included data on delgocitinib for atopic hand eczema, and tralokinumab for head and neck atopic dermatitis.

“It is critical that our clinical data represent the diversity in the world around us, and these results further reinforce our commitment to providing meaningful innovation for immune-mediated skin diseases," said Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis.

The findings stem from post-hoc analyses of previous trials, which found that 75.1% of patients reached PASI100 after 1 year on bimekizumab.

Through collaboration with Nimbus Therapeutics and Schrodinger, zasocitinib’s AI-driven design maximizes its fit within the targeted enzyme.